Patent ID: 8658168

Claim:
A method of treating a neoplastic cell comprising: obtaining a chemically engineered or recombinantly engineered conjugate of two or more monoclonal antibodies, wherein the conjugate comprises an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti-αHer2 monoclonal antibody that does not comprise an Fc region and wherein the conjugate comprises an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti-αHer2 monoclonal antibody that has anti-neoplastic activity in a conjugated form and has substantially no anti-neoplastic activity in an unconjugated form; and contacting a neoplastic cell with the conjugate, wherein the conjugate directly signals growth arrest or apoptosis in the cell.